Universitätsklinikum Hamburg-Eppendorf
- Address
- Martinistraße 52, 20246 Hamburg, Germany
Pediatric Oncology – High‑Risk Neuroblastoma
The Universitätsklinikum Hamburg‑Eppendorf conducts trials focused on improving outcomes for children with high‑risk neuroblastoma, evaluating intensive chemotherapy regimens and advanced radiation strategies.
- High‑dose chemotherapy sequencing
- Radiotherapy dose escalation
- Chemo‑immunotherapy combinations
- Metastatic response evaluation
The goal is to increase event‑free survival and refine treatment protocols for this aggressive pediatric cancer.
Nephrology – Chronic Kidney Disease Biomarker Study
Researchers are testing a biomarker‑directed approach to personalize therapy for patients with chronic kidney disease, aiming to preserve kidney function over time.
- Biomarker identification and validation
- Targeted treatment selection
- Monitoring eGFR trajectory
- Optimizing long‑term renal outcomes
This study seeks to demonstrate that tailored interventions can slow disease progression compared with standard care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Institut Gustave Roussy1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitätsklinikum Hamburg-Eppendorf
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Dapagliflozin Propanediol, Finerenone, and Semaglutide in Biomarker-Targeted Therapy for Chronic Kidney Disease Patients | Steno Diabetes Center Copenhagen | Phase III | Recruiting | Jun 2025 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Busulfan | 1 | Unknown | 2024-11-21 | 2024-11-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.